News & media

Here you can find our news and media resources. To comply with applicable regulation in Denmark, press releases and company announcements concerning specific medicinal products or investigational candidates in late-stage development are removed from our website within three weeks of publication. Please contact us to request a copy.

  • COMPANY ANNOUNCEMENT

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

  • PRESS RELEASE

    Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

  • PRESS RELEASE

    Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

  • COMPANY ANNOUNCEMENT

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

  • COMPANY ANNOUNCEMENT

    Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

  • COMPANY ANNOUNCEMENT

    U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

  • PRESS RELEASE

    Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

  • PRESS RELEASE

    Zealand Pharma to participate in the Jefferies London Healthcare Conference

  • COMPANY ANNOUNCEMENT

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

  • COMPANY ANNOUNCEMENT

    Zealand Pharma Announces Financial Results for the First Nine Months of 2024

  • PRESS RELEASE

    Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

  • COMPANY ANNOUNCEMENT

    Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Corporate management

  • Adam ALR0640

    Adam Steensberg - President and Chief Executive Officer

  • Zealand Pharma 0285 FIN

    Adam Steensberg - President and Chief Executive Officer

  • Christina ALR0693 V2

    Christina Sonnenborg Bredal - Executive Vice President and Chief People Officer

  • David ALR1003

    David Kendall - Executive Vice President, Research & Development and Chief Medical Officer

  • Henriette ALR0758

    Henriette Wennicke - Executive Vice President and Chief Financial Officer

  • Ivan ALR0873

    Ivan Møller - Executive Vice President and Chief Operating Officer

Research and development

Logos and icons

Zealand Pharma 1503

Stay up-to-date with the latest news from Zealand

Sign-up to receive press releases and company announcements directly to your inbox

Subscribe to news

Investor and Media contacts

  • Anna Krassowksa (1)

    Anna Krassowska

    Vice President, Investor Relations & Corporate Communications

    Email Anna